Back to top

A qualitative study to better understand women’s use of the dapivirine ring in both ASPIRE (MTN-020), a placebo-controlled trial, and HOPE (MTN-025), an open-label extension study in which women were given the opportunity to use the ring for one year if they so chose. The study was conducted in two parts. Phase I involved 187 former ASPIRE participants who had been assigned to use the dapivirine ring and who took part in either a focus group or in-depth interview.  Results, which were reported in 2018, found that women who didn’t use the ring regularly feared their partners would oppose its use or feel it during sex. High adherers expressed altruistic motivations for ring use. Phase 2 involved 115 former participants who opted to enroll in HOPE, with results expected in mid- to late 2020.  MTN-032 was conducted at six of the 15 clinical research sites for ASPIRE and HOPE.


After ASPIRE: HOPE and other MTN Studies of the Dapivirine Ring



See Also

MTN-032 Protocol


MTN-032 Study Page